President Trump’s decision to withdraw the United States from the Paris Agreement on Climate Change raises a series of legal, procedural and policy questions that have yet to be decisively answered, said the Congressional Research Service last week.
Among those questions: Will the US follow the prescribed multi-year procedure for withdrawal? Or can the US withdraw immediately? What role if any will the US play in future climate change deliberations under the Paris Agreement? What are the prospects for a legal challenge to the US withdrawal?
See President Trump’s Withdrawal from the Paris Agreement Raises Legal Questions, CRS Legal Sidebar, June 9, 2017.
Other new and updated reports from the Congressional Research Service include the following.
FY2018 Defense Budget Request: The Basics, June 9, 2017
Qatar: Governance, Security, and U.S. Policy, updated June 9, 2017
Israel and the Boycott, Divestment, and Sanctions (BDS) Movement, updated June 9, 2017
U.S. Foreign Aid to the Middle East and North Africa: The President’s FY2018 Request, CRS Insight, June 8, 2017
Malawi: Key Developments and U.S. Relations, June 2, 2017
U.S. Strategy for Engagement in Central America: Policy Issues for Congress, June 8, 2017
European Security and Islamist Terrorism, CRS Insight, updated June 8, 2017
Juneteenth: Fact Sheet, June 9, 2017
Air Force B-21 Long Range Strike Bomber, updated June 7, 2017
Special Counsels, Independent Counsels, and Special Prosecutors: Options for Independent Executive Investigations, June 1, 2017
FAS commends the Senate Committee on Energy and Natural Resources for clearing a historic 75 pieces of legislation, including multiple crucial bills to confront the wildfire crisis.
The United States needs a strategic investment fund (SIF) to shepherd promising technologies in nationally vital sectors through the valley of death.
Standardizing support for Accessibility & Accommodations in federally funded research efforts would open opportunities for disabled scientists and their research programs.
The incoming administration must act to address bias in medical technology at the development, testing and regulation, and market-deployment and evaluation phases.